Sector revisions Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 16:00:00 2026-07-28 EDT			5-day change	1st Jan Change
2.870 ^USD	+1.77%		-3.69%	+4.36%

07-28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
07-17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	Nbr of analysts
PERSPECTIVE THERAPEUTICS, INC.		15
LONZA GROUP AG		23
REVOLUTION MEDICINES, INC.		21
BEONE MEDICINES AG		27
IQVIA HOLDINGS INC.		19
CELLTRION, INC.		24
ASCENDIS PHARMA A/S	-	18
MEDPACE HOLDINGS, INC.		12
EUROFINS SCIENTIFIC SE		14
ICON PUBLIC LIMITED COMPANY		16
BIO-TECHNE CORPORATION		12
ABIVAX		6
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.		15
APOGEE THERAPEUTICS, INC.		12
PHARMARON BEIJING CO., LTD.		11
IONIS PHARMACEUTICALS, INC.		20
KYMERA THERAPEUTICS, INC.		21
PRAXIS PRECISION MEDICINES, INC.		19
ALKERMES PLC		17
PROTAGONIST THERAPEUTICS, INC.		13
Average		17
Weighted average by Cap.		19